Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05325346
Other study ID # VLX-1005-002
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 7, 2022
Est. completion date April 14, 2022

Study information

Verified date March 2022
Source Veralox Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is designed to characterize the safety and tolerability of VLX-1005 and argatroban administered intravenously, either alone or in combination; and the pharmacokinetics and pharmacodynamics and potential interaction of both agents in a population of healthy subjects.


Description:

VLX-1005 is being developed as a treatment for heparin induced thrombocytopenia (HIT), a rare but life threatening illness. Currently, the anticoagulant argatroban remains the standard of care for treating HIT. However, this treatment remains inadequate due to both thrombosis and major bleeding complications that each may exceed 30% of treated HIT patients. These findings are significant to the later stage clinical development of VLX-1005 as a trial of VLX-1005 on top of argatroban therapy would require an understanding of any potential drug-drug interactions- whether direct or via metabolism. Specifically, coadministration of VLX-1005 with argatroban mandates an analysis of the potential effects on PK, pharmacodynamics and bleeding. The current study is designed to address these important questions.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date April 14, 2022
Est. primary completion date April 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 55 Years
Eligibility Inclusion Criteria: 1. Healthy, adult, male or female (non-lactating and not of childbearing potential) subjects age 19 to 55 inclusive. 2. Females must have undergone one of the following sterilization procedures at least 6 months prior to the first dosing: 1. hysteroscopic sterilization 2. bilateral tubal ligation or bilateral salpingectomy 3. hysterectomy 4. bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to the first dosing and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status. 3. Good general health, with no significant medical history. Subjects must have no clinically significant abnormalities at screening, and/or before administration of the initial dose of study drug. 4. Body weight = 50 kg at the screening visit. 5. Body Mass Index (BMI) between 18 and 32 kg/m2 inclusive. 6. Laboratory values (clinical chemistry and hematology) within the normal reference range. Deviations from this range may be acceptable if they are considered 'not clinically significant' (NCS) by the PI, however, AST and ALT shall be <1.5x ULN. 7. Males who have not been vasectomized prior to participating in the study must agree to use at least 2 approved methods of contraception, or to abstain from sexual intercourse, from randomization until 90 days after their last dose of VLX-1005 and should refrain from donating sperm during that period. 8. Is a non-smoker and must not have used any nicotine products within three months prior to screening. 9. Able and willing to attend the necessary visits to the study center. Exclusion Criteria: 1. Blood donation or recipient of blood transfusion in previous 12 weeks. 2. History of clinically significant endocrine, neurological, gastrointestinal, cardiovascular, hematological, hepatobiliary, immunological, renal, respiratory, or genitourinary abnormalities or diseases. 3. History of neoplastic disease (with the exception of adequately treated nonmelanomatous skin carcinoma). 4. Mentally or legally incapacitated (e.g. has significant emotional problems at the time of Screening Visit or expected during the conduct of the study, or has a history of a clinically significant psychiatric disorder within the last 5 years). 5. Fever (body temperature >38 C) or symptomatic viral/bacterial infection or use of antibiotics within 2 weeks prior to Screening. 6. Supine resting blood pressure (BP) >140/90 mmHg or heart rate (HR) >100 beats per minute at Screening and at Day -2. 7. Clinically significant abnormality on ECG performed at the Screening Visit or prior to administration of the initial dose of study drug. (Abnormalities include not being in sinus rhythm, IVCD/BBB or QTcF>450 ms for males (470 ms for females)). 8. Out of range (on repeat) testing for coagulation tests. 9. Clinically significant laboratory abnormalities including: Impaired renal function (estimated creatinine clearance (CrCl) of <80 mL/minute based on CrCl = (140-age [years])(body weight [kg])/(72)(serum creatinine [mg/dL])). 10. Positive test for hepatitis C antibody, hepatitis B surface antigen, or human immunodeficiency virus (HIV) antibody at Screening. 11. Participants with a positive toxicology screening panel (urine test including qualitative identification of barbiturates, tetrahydrocannabinol, amphetamines, benzodiazepines, opiates, cocaine, cotinine and ethanol). 12. Participants with a history of substance abuse or dependency or history of recreational IV drug use (by self-declaration).13. Participant has a suspected history of alcohol abuse in the 6 months prior to screening. 14. Use of NSAIDs, aspirin or aspirin-containing medications (and other medications affecting platelet function [for example cilostazol, clopidogrel, ticagrelor, prasugrel, dipyridamole]) in the 14 days prior to dosing with study medication. VerifyNow testing will be performed at check-in to exclude possible use of medications that affect platelet function. 15. Unable to refrain from or anticipates the use of any medications, including prescription and non-prescription drugs and herbal remedies (such as St. John's Wort [Hypericum perforatum]), beginning 14 days (or 5 half-lives, whichever is longer) before administration of the initial dose of study drug and continuing throughout the study until the final study visit. There may be certain medications that are permitted at the discretion of the PI and Sponsor (including paracetamol/acetaminophen, medications for the treatment of AEs following administration of study drug). 16. Subjects who are unlikely to comply with the study protocol or, in the opinion of the PI, would not be a suitable candidate for participation in the study. 17. Have participated in any other investigational drug trial within 30 days of dosing in the present study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
VLX-1005
Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
Argatroban
Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD

Locations

Country Name City State
United States Celerion, Inc. Lincoln Nebraska

Sponsors (2)

Lead Sponsor Collaborator
Veralox Therapeutics Celerion

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effects of argatroban on Cmax of VLX-1005 Measure the effects of argatroban on the maximum plasma concentration (Cmax) of VLX-1005 0 - 51 hours
Primary Effects of VLX-1005 on Cmax of argatroban Measure the effects of VLX-1005 on the maximum plasma concentration (Cmax) of argatroban 0 - 51 hours
Primary Effects of argatroban on Tmax of VLX-1005 Measure the effects of argatroban on the time to maximum plasma concentration (Tmax) of VLX-1005 0 - 51 hours
Primary Effects of VLX-1005 on Tmax of argatroban Measure the effects of VLX-1005 on the time to maximum plasma concentration (Tmax) of argatroban 0 - 51 hours
Primary Effects of argatroban on AUC(inf) of VLX-1005 Measure the effects of argatroban on the Area Under the Curve [AUC(inf)] of VLX-1005 0 - 51 hours
Primary Effects of VLX-1005 on AUC(inf) of argatroban Measure the effects of VLX-1005 on the Area Under the Curve [AUC(inf)] of argatroban 0 - 51 hours
Primary Effects of VLX-1005 on whole blood aggregometry The change in impedance from baseline by whole blood aggregometry will be measured to assess the effects of VLX-1005 on platelet aggregation 0 - 9 hours
Primary Effects of argatroban on whole blood aggregometry The change in impedance from baseline by whole blood aggregometry will be measured to assess the effects of argatroban on platelet aggregation 0 - 9 hours
Primary Effects of VLX-1005 on PFA-100 Change in PFA-100 (a platelet pharmacodynamic measure) from baseline, to assess the effects of VLX-1005 on platelet aggregation 0 - 9 hours
Primary Effects of argatroban on PFA-100 Change in PFA-100 (a platelet pharmacodynamic measure) from baseline, to assess the effects of argatroban on platelet aggregation 0 - 9 hours
Secondary Safety as measured by incidence of Treatment Emergent Adverse Events To assess the effects on subject safety of VLX-1005 and argatroban alone and in combination as measured by incidence of Treatment Emergent Adverse Events as assessed by CTCAE, ver 5.0. 0 - 30 days
Secondary Effects of VLX-1005 on 12-HETE 12-hydroxyeicosatetraenoic acid (12-HETE), a platelet biomarker, will be measured to assess the effects of VLX-1005 on its production 0 - 12 hours
Secondary Effects of argatroban on 12-HETE 12-HETE, a platelet biomarker, will be measured to assess the effects of argatroban on its production 0 - 12 hours
See also
  Status Clinical Trial Phase
Withdrawn NCT00759083 - Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients Phase 4
Completed NCT00412464 - Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis Phase 1
Completed NCT00456326 - Heparin-Induced Thrombocytopenia Registry N/A
Terminated NCT00673439 - Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT) Phase 2
Active, not recruiting NCT00198575 - A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients N/A
Completed NCT00283322 - Heparin Antibodies in Intensive Care Unit Patients (HAICU) N/A
Not yet recruiting NCT05586854 - Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia N/A
Not yet recruiting NCT03269019 - Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia N/A
Not yet recruiting NCT06066762 - Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
Terminated NCT03809481 - Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban Phase 3
Recruiting NCT02717039 - Pharmacogenomics of Heparin-Induced Thrombocytopenia
Completed NCT02526485 - Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
Completed NCT00748839 - Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical N/A
Recruiting NCT05783895 - Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery
Not yet recruiting NCT04782843 - Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.
Completed NCT00198588 - Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia Phase 3
Recruiting NCT04842760 - PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
Terminated NCT01598168 - Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia Phase 3
Completed NCT01654848 - Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients N/A
Withdrawn NCT00603824 - Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT) Phase 4